- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 7481-89-2] Zalcitabine
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-17392 |
| Brand: | MCE |
| CAS: | 7481-89-2 |
Overview
| MDL | MFCD00012188 |
|---|---|
| Molecular Weight | 211.22 |
| Molecular Formula | C9H13N3O3 |
| SMILES | OC[C@@H]1CC[C@H](N2C(N=C(C=C2)N)=O)O1 |
3 Publications Citing Use of MCE
Summary
Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection .
IC50 & Target
Target: HIV
In Vitro
Zalcitabine is a dideoxynucleoside antiretroviral agent that is phosphorylated to the active metabolite 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) within both uninfected and HIV-infected cells. At therapeutic concentrations, ddCTP inhibits HIV replication by inhibiting the enzyme reverse transcriptase and terminating elongation of the proviral DNA chain [1] . Zalcitabine exhibits the inhibition effect on the cellular uptake of [3H]-PAH in CHO/hOAT1 cells with an IC 50 value of 1.23 mM. Furthermore, the cellular uptake of zalcitabine increased threefold with the enhancement of hOATI activity in CHO/hOAT1 cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00001048 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Upjohn |
HIV Infections|Leukoencephalopathy, Progressive Multifocal
|
Phase 2 | |
| NCT00000978 | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche |
HIV Infections
|
Phase 1 | |
| NCT00002162 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00000704 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00001040 | Hoffmann-La Roche|National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000682 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 3 | |
| NCT00002265 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00000653 | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche |
HIV Infections
|
Phase 2 | |
| NCT00000969 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Hoffmann-La Roche |
HIV Infections
|
Not Applicable | |
| NCT00002086 | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00002117 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 3 | |
| NCT00000718 | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche |
HIV Infections
|
Not Applicable | |
| NCT00002081 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00002256 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00000781 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00000954 | National Institute of Allergy and Infectious Diseases (NIAID)|Novum|Bristol-Myers Squibb |
Sarcoma, Kaposi|HIV Infections
|
Phase 1 | |
| NCT00001035 | National Institute of Allergy and Infectious Diseases (NIAID)|Schering-Plough |
HIV Infections|Hepatitis C
|
Phase 1 | |
| NCT00000678 | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche |
HIV Infections
|
Phase 2 | |
| NCT00000902 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00002334 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 3 | |
| NCT00002001 | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00000651 | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche|Glaxo Wellcome |
HIV Infections
|
Phase 3 | |
| NCT00002386 | Merck Sharp & Dohme LLC|NIH AIDS Clinical Trials Information Service |
HIV Infections|Hemophilia A
|
Phase 4 | |
| NCT00002118 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00000997 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Not Applicable | |
| NCT00002109 | Immunobiology Research Institute|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 3 | |
| NCT00002279 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00001022 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 3 | |
| NCT00001029 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00001032 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000753 | National Institute of Allergy and Infectious Diseases (NIAID)|Upjohn|Glaxo Wellcome |
HIV Infections
|
Phase 1 | |
| NCT00002347 | Parexel|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00001087 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000679 | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche |
HIV Infections
|
Phase 2 | |
| NCT00002436 | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 3 | |
| NCT00000719 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Not Applicable | |
| NCT00002333 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00000754 | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00000625 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 62.5 mg/mL ( 295.90 mM ; Need ultrasonic)
H 2 O : ≥ 25 mg/mL ( 118.36 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.7344 mL | 23.6720 mL | 47.3440 mL |
| 5 mM | 0.9469 mL | 4.7344 mL | 9.4688 mL |
| 10 mM | 0.4734 mL | 2.3672 mL | 4.7344 mL |
References
- [1] Adkins JC, et al. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.Drugs. 1997 Jun;53(6):1054-80
- [2] Jin MJ, et al. Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.